- Home
- GENC vs NBTX Comparison
GENC vs NBTX Comparison
Compare GENC & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENC
- NBTX
- Stock Information
- Founded
- GENC 1894
- NBTX 2003
- Country
- GENC United States
- NBTX France
- Employees
- GENC N/A
- NBTX N/A
- Industry
- GENC Construction/Ag Equipment/Trucks
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- GENC Industrials
- NBTX Health Care
- Exchange
- GENC Nasdaq
- NBTX Nasdaq
- Market Cap
- GENC 215.0M
- NBTX 211.9M
- IPO Year
- GENC N/A
- NBTX 2020
- Fundamental
- Price
- GENC $15.06
- NBTX $5.14
- Analyst Decision
- GENC
- NBTX Strong Buy
- Analyst Count
- GENC 0
- NBTX 1
- Target Price
- GENC N/A
- NBTX $8.00
- AVG Volume (30 Days)
- GENC 27.8K
- NBTX 6.5K
- Earning Date
- GENC 08-08-2025
- NBTX 04-02-2025
- Dividend Yield
- GENC N/A
- NBTX N/A
- EPS Growth
- GENC N/A
- NBTX N/A
- EPS
- GENC 0.99
- NBTX N/A
- Revenue
- GENC $113,166,000.00
- NBTX N/A
- Revenue This Year
- GENC N/A
- NBTX N/A
- Revenue Next Year
- GENC N/A
- NBTX $221.06
- P/E Ratio
- GENC $15.34
- NBTX N/A
- Revenue Growth
- GENC 7.70
- NBTX N/A
- 52 Week Low
- GENC $10.80
- NBTX $2.76
- 52 Week High
- GENC $24.88
- NBTX $6.00
- Technical
- Relative Strength Index (RSI)
- GENC 58.37
- NBTX 64.58
- Support Level
- GENC $14.72
- NBTX $4.79
- Resistance Level
- GENC $15.17
- NBTX $5.53
- Average True Range (ATR)
- GENC 0.68
- NBTX 0.19
- MACD
- GENC 0.03
- NBTX 0.05
- Stochastic Oscillator
- GENC 86.62
- NBTX 90.18
About GENC Gencor Industries Inc.
Gencor Industries Inc and its subsidiaries is a manufacturer of heavy machinery used in the production of highway construction materials and environmental control equipment. The Company has one reporting segment, equipment for the highway construction industry. The firm's principal products include asphalt plants, combustion systems, hot mix asphalt plants, fluid heat transfer systems, and asphalt pavers.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.